|
|
 |
|
Viewing report
|
|
|
|
Muscular Dystrophy (MD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, Nov 2011, Pages: 73
Muscular Dystrophy (MD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Muscular Dystrophy (MD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global MD therapeutics market. The report identifies the key trends shaping and driving the global MD therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MD therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global Muscular Dystrophy (MD) therapeutics market to grow at a Compound Annual Growth Rate (CAGR) of 22.8%, from $33m in 2010 to $170.9m in 2018. The market will show steady growth till 2010 and a steep increase in the market valuations will be seen after 2014. This is primarily attributed to the expected launch of two molecules GSK2402968 in 2014 and Catena/Sovrima (idebenone) in 2015 for the Duchenne Muscular Dystrophy/Becker Muscular Dystrophy (DMD/BMD). The future market is set to witness significant high value growth mainly due to the high cost of therapy of the pipeline molecules. The other factors that will contribute to the growth of the market are high diagnosis and treatment rates and increasing disease awareness. Absence of approved drugs and the high use of off-label generic drugs, such as prednisolone, deflazacort, mexiletine, naproxen and others will act as a barrier to the MD therapeutics market.
Scope
The report provides information on the key drivers and challenges of the MD therapeutics market. Its scope includes -
- Annualized global MD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as mitochondria targeted antioxidants, exon-skipping, PDE5 (phosphodiesterase inhibitors), nonsense mutation inhibitors, insulin like growth factor, gene therapy, utrophin upregulators, androgen receptor modulators and GADPH (glyceraldehyde 3-phosphate dehydrogenase) inhibitors.
- Analysis of the current and future competition in the global MD therapeutics market. Key market players covered are GSK, Santhera, Prosensa, Takeda, PTC Therapeutics, Genzyme and AVI BioPharma.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the MD therapeutics market.
- Analysis of key recent licensing and partnership agreements in the MD therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global MD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MD therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global MD therapeutics market landscape? Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
